MedTrace Logo

Conjunctival Vascularity Changes Usnig OCTA After Trabeculectomy

NCT04493073 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-07-30

No results posted yet for this study

Summary

* Reduce the trauma and the time taken for patient rehabilitation.
* The prevailing trend is to perform a mitomycin- C (MMC)-augmented trabeculectomy and trabeculectomy with ologen implants in a trial to decrease bleb failure as a common post- trabeculectomy complication.
* Is to develop a measurement protocol by OCT-A imaging and characterization of the bleb vascularity changes in glaucoma patients before and after surgery.

Conditions

  • OCTA

Interventions

PROCEDURE

Trabectulectomy

decrease IOP

DRUG

Mitomycin

Decrease bleb failure

DEVICE

Ologen Collagen Implant

Ologen Collagen Implant (Aeon Astron Europe, Netherlands)

DEVICE

Mitomycin-C Kyowa®

Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)

Sponsors & Collaborators

  • Asmaa Ahmed Ali Youssif

    lead OTHER

Principal Investigators

  • Mohamed Saad · Assiut University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-12-01
Completion
2022-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04493073 on ClinicalTrials.gov